Correlation between direct ELISA, single epitope-based inhibition ELISA and pseudovirion-based neutralization assay for measuring anti-HPV-16 and anti-HPV-18 antibody response after vaccination with the AS04-adjuvanted HPV-16/18 cervical cancer vaccine

Human Vaccines

Volumn 4, Issue 6, 2008, Pages 425-434

  Dessy, Francis J ^a   Giannini, Sandra L ^a   Bougelet, Catherine A ^a   Kemp, Troy J ^b   David, Marie Pierre M ^a   Poncelet, Sylviane M ^a   Pinto, Ligia A ^b   Wettendorff, Martine A ^a  

^a GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

^b SAIC FREDERICK INC   (United States)

Author keywords

AS04 Adjuvant System; Cervical cancer; ELISA; HPV 16; HPV 18; Immune response; Neutralization assay; Pseudovirion; Vaccine; VLP

Indexed keywords

WART VIRUS VACCINE; IMMUNOLOGICAL ADJUVANT; VIRUS ANTIBODY;

AGE DISTRIBUTION; ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ANTIBODY RESPONSE; ARTICLE; CANCER IMMUNIZATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CORRELATION ANALYSIS; DOSE RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; IMMUNOASSAY; INTERMETHOD COMPARISON; PSEUDOVIRION BASED NEUTRALIZATION ASSAY; QUANTITATIVE ANALYSIS; SENSITIVITY AND SPECIFICITY; SINGLE EPITOPE BASED INHIBITION ENZYME LINKED IMMUNOSORBENT ASSAY; UTERINE CERVIX CANCER; VACCINATION REACTION; VALIDATION PROCESS; ADOLESCENT; ADULT; BLOOD; CHILD; COMPARATIVE STUDY; EVALUATION; IMMUNOLOGY; METHODOLOGY; MIDDLE AGED; MULTICENTER STUDY; SERODIAGNOSIS; STATISTICS;

ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; ADULT; ANTIBODIES, VIRAL; CHILD; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; MIDDLE AGED; NEUTRALIZATION TESTS; PAPILLOMAVIRUS VACCINES; SENSITIVITY AND SPECIFICITY; STATISTICS AS TOPIC;

EID: 56149091686     PISSN: 15548600     EISSN: 15548619     Source Type: Journal    
DOI: 10.4161/hv.4.6.6912     Document Type: Article

References (49)

1. Cogliano V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F. Carcinogenicity of human papillomaviruses. Lancet Oncol 2005; 6:204.
2. de Villiers EM, Fauquet C, Broker TR, Bernard HU, zur Hausen H. Classification of papillomaviruses. Virology 2004; 324:17-27.
3. Muñoz N, Bosch FX, de Sanjosé S, Herrero R, Castellsagué X, Shah KV, Snijders PJ, Meijer CJ. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003; 348:518-27.
4. Schiffman M, Herrero R, Desalle R, Hildesheim A, Wacholder S, Rodriguez AC, Bratti MC, Sherman ME, Morales J, Guillen D, Alfaro M, Hutchinson M, Wright TC, Solomon D, Chen Z, Schussler J, Castle PE, Burk RD. The carcinogenicity of human papillomavirus types reflects viral evolution. Virology 2005; 337:76-84.
5. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Muñoz N. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999; 189:12-9.
6. Muñoz N, Bosch FX, Castellsagué X, Diaz M, de Sanjosé S, Hammouda D, Shah KV, Meijer CJ. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer 2004; 111:278-85.
7. Harper DM, Franco EL, Wheeler C, Ferris DG, Jenkins D, Schuind A, Zahaf T, Innis B, Naud P, De Carvalho NS, Roteli-Martins CM, Teixeira J, Blatter MM, Korn AP, Quint W, Dubin G. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 2004; 364:1757-65.
8. Harper DM, Franco EL, Wheeler CM, Moscicki AB, Romanowski B, Roteli-Martins CM, Jenkins D, Schuind A, Costa Clemens SA, Dubin G. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 2006; 367:1247-55.
9. Koutsky LA, Ault KA, Wheeler CM, Brown DR, Barr E, Alvarez FB, Chiacchierini LM, Jansen KU. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 2002; 347:1645-51.
10. Mao C, Koutsky LA, Ault KA, Wheeler CM, Brown DR, Wiley DJ, Alvarez FB, Bautista OM, Jansen KU, Barr E. Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial. Obstet Gynecol 2006; 107:18-27.
11. Paavonen J, Jenkins D, Bosch FX, Naud P, Salmeron J, Wheeler CM, Chow SN, Apter DL, Kitchener HC, Castellsagué X, De Carvalho NS, Skinner SR, Harper DM, Hedrick JA, Jaisamrarn U, Limson GA, Dionne M, Quint W, Spiessens B, Peeters P, Struyf F, Wieting SL, Lehtinen MO, Dubin G. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 2007; 369:2161-70.
12. Villa LL, Costa RL, Petta CA, Andrade RP, Ault KA, Giuliano AR, Wheeler CM, Koutsky LA, Malm C, Lehtinen M, Skjeldestad FE, Olsson SE, Steinwall M, Brown DR, Kurman RJ, Ronnett BM, Stoler MH, Ferenczy A, Harper DM, Tamms GM, Yu J, Lupinacci L, Railkar R, Taddeo FJ, Jansen KU, Esser MT, Sings HL, Saah AJ, Barr E. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16 and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005; 6:271-8.
13. Harper D, Gall S, Naud P, Quint W, Dubin G, Jenkins D, Schuind A. Sustained immunogenicity and high efficacy against HPV-16/18 related cervical neoplasia: long-term follow up through 6.4 years in women vaccinated with CervarixTM (GSK's HPV 16/18 AS04 candidate vaccine). Society of Gynecologic Oncologists 39th Annual Meeting on Women's Cancer, Tampa, FL, USA 2008.
14. Schwarz TF, Leo O. Immune response to human papillomavirus after prophylactic vaccination with AS04-adjuvanted HPV-16/18 vaccine: improving upon nature. Gynecol Oncol 2008; 110:S1-10.
15. Wheeler CM, Teixeira J, Romanowski B, De Carvalho N, Dubin G, Schuind A. High and sustained HPV-16 and 18 antibody levels through 6.4 years in women vaccinated with Cervarix™ (GSK HPV-16/18 AS04 vaccine). 26th Annual Meeting of the European Society for Paediatric Infectious Diseases, Graz, Austria 2008.
16. David M-P, Hardt K, Tibaldi F, Dubin G, Descamps D. Long-term persistence of detectable anti-HPV-16 and anti-HPV-18 antibodies induced by CervarixTM: modelling of sustained antibody responses. 26th Annual Meeting of the European Society for Paediatric Infectious Diseases, Graz, Austria 2008.
17. Lin YL, Borenstein LA, Selvakumar R, Ahmed R, Wettstein FO. Effective vaccination against papilloma development by immunization with L1 or L2 structural protein of cottontail rabbit papillomavirus. Virology 1992; 187:612-9.
18. Breitburd F, Kirnbauer R, Hubbert NL, Nonnenmacher B, Trin-Dinh-Desmarquet C, Orth G, Schiller JT, Lowy DR. Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection. J Virol 1995; 69:3959-63.
19. Jansen KU, Rosolowsky M, Schultz LD, Markus HZ, Cook JC, Donnelly JJ, Martinez D, Ellis RW, Shaw AR. Vaccination with yeast-expressed cottontail rabbit papillomavirus (CRPV) virus-like particles protects rabbits from CRPV-induced papilloma formation. Vaccine 1995; 13:1509-14.
20. Suzich JA, Ghim SJ, Palmer-Hill FJ, White WI, Tamura JK, Bell JA, Newsome JA, Jenson AB, Schlegel R. Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Proc Natl Acad Sci USA 1995; 92:11553-7.
21. Christensen ND, Reed CA, Cladel NM, Han R, Kreider JW. Immunization with virus like particles induces long-term protection of rabbits against challenge with cottontail rabbit papillomavirus. J Virol 1996; 70:960-5.
22. Kirnbauer R, Chandrachud LM, O'Neil BW, Wagner ER, Grindlay GJ, Armstrong A, McGarvie GM, Schiller JT, Lowy DR, Campo MS. Virus-like particles of bovine papillomavirus type 4 in prophylactic and therapeutic immunization. Virology 1996; 219:37-44.
23. Plotkin SA. Vaccines: correlates of vaccine-induced immunity. Clin Infect Dis 2008; 47:401-9.
24. Brown DR, Bryan JT, Schroeder JM, Robinson TS, Fife KH, Wheeler CM, Barr E, Smith PR, Chiacchierini L, Dicello A, Jansen KU. Neutralization of human papillomavirus type 11 (HPV-11) by serum from women vaccinated with yeast-derived HPV-11 L1 virus-like particles: correlation with competitive radioimmunoassay titer. J Infect Dis 2001; 184:1183-6.
25. Bryan JT, Jansen KU, Lowe RS, Fife KH, McClowry T, Glass D, Brown DR. Human papillomavirus type 11 neutralization in the athymic mouse xenograft system: correlation with virus-like particle IgG concentration. J Med Virol 1997; 53:185-8.
26. Pastrana DV, Buck CB, Pang YY, Thompson CD, Castle PE, FitzGerald PC, Kruger KS, Lowy DR, Schiller JT. Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18. Virology 2004; 321:205-16.
27. Roden RB, Greenstone HL, Kirnbauer R, Booy FP, Jessie J, Lowy DR, Schiller JT. In vitro generation and type-specific neutralization of a human papillomavirus type 16 virion pseudotype. J Virol 1996; 70:5875-83.
28. White WI, Wilson SD, Bonnez W, Rose RC, Koenig S, Suzich JA. In vitro infection and type-restricted antibody-mediated neutralization of authentic human papillomavirus type 16. J Virol 1998; 72:959-64.
29. Yeager MD, Aste-Amezaga M, Brown DR, Martin MM, Shah MJ, Cook JC, Christensen ND, Ackerson C, Lowe RS, Smith JF, Keller P, Jansen KU. Neutralization of human papillomavirus (HPV) pseudovirions: a novel and efficient approach to detect and characterize HPV neutralizing antibodies. Virology 2000; 278:570-7.
30. Kemp TJ, García-Piñeres A, Falk RT, Poncelet S, Dessy F, Giannini SL, Rodriguez AC, Porras C, Herrero R, Hildesheim A, Pinto LA. Evaluation of systemic and mucosal anti-HPV16 and anti-HPV18 antibody responses from vaccinated women. Vaccine 2008; 26:3608-16.
31. Opalka D, Lachman CE, MacMullen SA, Jansen KU, Smith JF, Chirmule N, Esser MT. Simultaneous quantitation of antibodies to neutralizing epitopes on virus-like particles for human papillomavirus types 6, 11, 16 and 18 by a multiplexed luminex assay. Clin Diagn Lab Immunol 2003; 10:108-15.
32. Smith JF, Kowalski R, Esser MT, Brown MJ, Bryan JT. Evolution of Type-Specific Immunoassays to Evaluate the Functional Immune Response to GARDASIL®, a Vaccine for Human Papillomavirus Types 16, 18, 6 and 11. Hum Vaccin 2007; 4:134-42.
33. Wideroff L, Schiffman MH, Nonnenmacher B, Hubbert N, Kirnbauer R, Greer CE, Lowy D, Lorincz AT, Manos MM, Glass AG. Evaluation of seroreactivity to human papillomavirus type 16 virus-like particles in an incident case-control study of cervical neoplasia. J Infect Dis 1995; 172:1425-30.
34. Wikstrom A, Van Doornum GJ, Quint WG, Schiller JT, Dillner J. Identification of human papillomavirus seroconversions. J Gen Virol 1995; 76:529-39.
35. Steele J, Collins S, Wen K, Ryan G, Constandinou-Williams C, Woodman CB. Measurement of the humoral immune response following an incident HPV16 or HPV18 infection in young women using a pseudovirion-based neutralising antibody assay. Clin Vaccine Immunol 2008; 15:1387-90.
36. Ryding J, Dahlberg L, Wallen-Ohman M, Dillner J. Deletion of a major neutralizing epitope of human papillomavirus type 16 virus-like particles. J Gen Virol 2007; 88:792-802.
37. Carter JJ, Wipf GC, Madeleine MM, Schwartz SM, Koutsky LA, Galloway DA. Identification of human papillomavirus type 16 L1 surface loops required for neutralization by human sera. J Virol 2006; 80:4664-72.
38. Dias D, Van Doren J, Schlottmann S, Kelly S, Puchalski D, Ruiz W, Boerckel P, Kessler J, Antonello JM, Green T, Brown M, Smith J, Chirmule N, Barr E, Jansen KU, Esser MT. Optimization and validation of a multiplexed luminex assay to quantify antibodies to neutralizing epitopes on human papillomaviruses 6, 11, 16 and 18. Clin Diagn Lab Immunol 2005; 12:959-69.
39. Ferguson M, Heath A, Johnes S, Pagliusi S, Dillner J. Results of the first WHO international collaborative study on the standardization of the detection of antibodies to human papillomaviruses. Int J Cancer 2006; 118:1508-14.
40. Buck CB, Pastrana DV, Lowy DR, Schiller JT. Generation of HPV pseudovirions using transfection and their use in neutralization assays. Methods Mol Med 2005; 119:445-62.
41. Harper DM. Prophylactic human papillomavirus vaccines to prevent cervical cancer: review of the Phase II and III trials. Therapy 2008; 5:313-24.
42. World Health Organization Expert Committee on Biological Standardization. Guidelines to assure the quality, safety and efficacy of recombinant human papillomavirus virus-like particle vaccines. WHO, Geneva 2007; URL: http://www.who.int/biologicals/publications/trs/areas/ vaccines/human_papillomavirus/HPVg%20Final%20BS%202050%20.pdf (last accessed August 2008)
43. World Health Organization. WHO meeting on the standardization of HPV assays and the role of WHO HPV LabNet in supporting vaccine introduction. WHO, Geneva 2008; URL: http://www.who.int/biologicals/areas/vaccines/hpv&_labnet/ FINAL%20repor_%20HPV_%2023+24%20+25%20Jan%202008%20_CLEAN_.pdf (last accessed August 2008)
44. Dessy F, David M-P, Schuind A, Jenkins D, Dubin G, for the HPV Vaccine Study Group. Evaluation of HPV neutralizing antibodies from an extended follow up study through 5.5 years in women vaccinated with GSK's prophylactic cervical cancer candidate vaccine. 24th International Papillomavirus Conference and Clinical Workshop, Beijing, China 2007.
45. Gall SA, Teixeira J, Wheeler CM, Naud P, Harper DM, Franco EL, Quint W, Zahaf T, Schuind A, Jenkins D, Dubin G, on behalf of the HPV Vaccine Study Group. Substantial impact on precancerous lesions and HPV infections through 5.5 years in women vaccinated with the HPV-16/18 L1 VLP AS04 candidate vaccine. American Association for Cancer Research Annual Meeting, Los Angeles, CA, USA 2007.
46. Smith JF, Brownlow M, Brown M, Kowalski R, Esser MT, Ruiz W, Barr E, Brown DR, Bryan JT. Antibodies from women immunized with Gardasil® cross-neutralize HPV 45 pseudovirions. Hum Vaccin 2007; 3:109-15.
47. Pedersen C, Petaja T, Strauss G, Rumke HC, Poder A, Richardus JH, Spiessens B, Descamps D, Hardt K, Lehtinen M, Dubin G. Immunization of early adolescent females with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvant. J Adolesc Health 2007; 40:564-71.
48. Schwarz TF, Dubin G, on behalf of the HPV Vaccine Study Investigators for Adult Women. Human papillomavirus (HPV) 16/18 L1 AS04 virus-like particle (VLP) cervical cancer vaccine is immunogenic and well-tolerated 18 months after vaccination in women up to age 55 years. American Society of Clinical Oncology Annual Meeting, Chicago, USA 2007.
49. Giannini SL, Hanon E, Moris P, Van Mechelen M, Morel S, Dessy F, Fourneau MA, Colau B, Suzich J, Losonksy G, Martin MT, Dubin G, Wettendorff MA. Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only. Vaccine 2006; 24:5937-49.